Impact of lineage plasticity to and from a neuroendocrine phenotype on progression and response in prostate and lung cancers
AffiliationDepartment for BioMedical Research, University of Bern and Inselspital, 3010 Bern, Switzerland; Bern Center for Precision Medicine, University of Bern and Inselspital, 3010 Bern, Switzerland.
MetadataShow full item record
AbstractIntratumoral heterogeneity can occur via phenotype transitions, often after chronic exposure to targeted anticancer agents. This process, termed lineage plasticity, is associated with acquired independence to an initial oncogenic driver, resulting in treatment failure. In non-small cell lung cancer (NSCLC) and prostate cancers, lineage plasticity manifests when the adenocarcinoma phenotype transforms into neuroendocrine (NE) disease. The exact molecular mechanisms involved in this NE transdifferentiation remain elusive. In small cell lung cancer (SCLC), plasticity from NE to nonNE phenotypes is driven by NOTCH signaling. Herein we review current understanding of NE lineage plasticity dynamics, exemplified by prostate cancer, NSCLC, and SCLC.
CitationRubin MA, Bristow RG, Thienger PD, Dive C, Imielinski M. Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. Mol Cell. 2020;80(4):562-77.
- Lineage plasticity in cancer: a shared pathway of therapeutic resistance.
- Authors: Quintanal-Villalonga Á, Chan JM, Yu HA, Pe'er D, Sawyers CL, Sen T, Rudin CM
- Issue date: 2020 Jun
- Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
- Authors: Cox ME, Deeble PD, Lakhani S, Parsons SJ
- Issue date: 1999 Aug 1
- Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer.
- Authors: Cai L, Liu H, Huang F, Fujimoto J, Girard L, Chen J, Li Y, Zhang YA, Deb D, Stastny V, Pozo K, Kuo CS, Jia G, Yang C, Zou W, Alomar A, Huffman K, Papari-Zareei M, Yang L, Drapkin B, Akbay EA, Shames DS, Wistuba II, Wang T, Johnson JE, Xiao G, DeBerardinis RJ, Minna JD, Xie Y, Gazdar AF
- Issue date: 2021 Mar 9
- [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype].
- Authors: Bonkhoff H, Fixemer T
- Issue date: 2004 Jul
- Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
- Authors: Kaur H, Samarska I, Lu J, Faisal F, Maughan BL, Murali S, Asrani K, Alshalalfa M, Antonarakis ES, Epstein JI, Joshu CE, Schaeffer EM, Mosquera JM, Lotan TL
- Issue date: 2020 Sep